World-first personalised cancer jab built from each patient's own tumour slashes the risk of death or melanoma relapse by 42%
Two years on, 82% of patients given the Moderna and MSD vaccine intismeran alongside Keytruda were alive and cancer-free, against 70% on Keytruda alone. The phase three trial covered 1,137 people whose high-risk melanoma had been surgically removed. Each jab is made in weeks using tumour DNA sequencing and AI. Prof Georgina Long is due to present the results in Madrid.
Intismeran uses the same mRNA technology as the Covid jabs.
Long: 'This has not been achieved before in the history of cancer drug development.'
Independent experts say longer studies must still prove it helps patients live longer.
More
The TelegraphCustom-built skin cancer vaccine almost halves death riskDaily MailWorld-first skin cancer vaccine halves deaths from deadly skin cancerLBCWorld-first personalised cancer jab cuts risk of melanoma returning or death by 42% in major trialBBC News - HealthWorld first personalised cancer vaccine stops disease returning in major trialThe IndependentWorld’s first mRNA cancer jab for melanoma cuts risk of death by 42%The IndependentWorld-first personalised cancer vaccine slashes risk of death and disease returningNYTFirst-of-Its-Kind Vaccine Ushers in New Hope for Cancer PatientsNY PostFirst-of-its-kind cancer vaccine helps reduce chances of melanoma patients’ tumors returning: studyiNewsHow a skin cancer vaccine cuts risk of the disease returningThe Guardian‘Bespoke’ mRNA vaccine significantly reduces risk of melanoma recurrence or death, clinical trial shows
